Human PD-L1 inhibitor I Catalog No.:M15157-2 InChi: InChI=1S/C27H35F2N7O3/c1-34-12-10-18(11-13-34)31-24(37)17-8-9-20(22(14-17)39-3)32-26-30-15-21-23(33-26)36(19-6-4-5-7-19)16-27(28

InChi: InChI=1S/C27H35F2N7O3/c1-34-12-10-18(11-13-34)31-24(37)17-8-9-20(22(14-17)39-3)32-26-30-15-21-23(33-26)36(19-6-4-5-7-19)16-27(28

Molecular Weight: 1671

Sodium phenylbutyrate is used to treat urea cycle disorders

NPS-2143 (SB-262470A) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor

Human PD-L1 inhibitor I Catalog No.:M15157-2 InChi: InChI=1S/C27H35F2N7O3/c1-34-12-10-18(11-13-34)31-24(37)17-8-9-20(22(14-17)39-3)32-26-30-15-21-23(33-26)36(19-6-4-5-7-19)16-27(28Human PD L1 inhibitor I is a hPD 1 peptide ligand, with a KD of 3. 39 M. Human PD L1 inhibitor I may disturb the binding of hPD L1 to hPD 1. Product information CAS Number: 2135542 86 6 Chemical Name: Human PD L1 inhibitor I Technical Data Appearance: Solid Power Purity: 98% (or refer to the Certificate of Analysis) Shipping Condition: Shipped under ambient temperature as non hazardous chemical or refer to Certificate of Analysis Storage Condition: